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Abstract
Background & objectives: Glycolysis is the sole source of energy for the intraerythrocytic stages of
Plasmodium falciparum, making glycolytic enzymes putative therapeutic targets. Enolase, a single
copy gene in P. falciparum is one such enzyme whose activity is elevated ~10–15 fold in infected
RBC’s. It holds the possibility of having multiple biological functions in the parasite and hence can
be a suitable candidate for diagnostic and chemotherapeutic purposes.
Methods: We have aimed at generating parasite-specific reagents in the form of monoclonal
antibodies. We have raised monoclonal antibodies against the recombinant P.  falciparum enolase.
Results: Two IgG monoclonals were obtained with 1:1000 titre and specific for P. falciparum enolase.
Apicomplexan parasites including P. falciparum enolase has a plant like pentapeptide sequence
(104EWGWS108) which is uniquely different from the host counterpart. A peptide spanning this
pentapeptide region (ELDGSKNEWGWSKSK) coupled to BSA was used to raise parasite-specific
antibody. Four monoclonals were obtained with 1:1000 titre and of IgM isotype.
Interpretation & conclusion: All the monoclonals are specific for P. falciparum enolase and one of
them display reactivity against native P. falciparum enolase signifying this pentapeptide to be surface
exposed and immunogenic.
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Introduction
Malaria remains a major threat to public health
worldwide. It is estimated that 1–2 million children
die each year mostly in sub-Saharan Africa due to
severe complications of Plasmodiun falciparum
malaria1. Attempts to reduce the rates of morbidity
and mortality have been hampered by the increa-
singly limited efficacy of current antimalarial drugs
to which P. falciparum has developed resistance2.
Renewed efforts are required to develop novel and
affordable antimalarials to overcome the detrimental
effects of drug resistance, particularly in developing
countries3. P. falciparum which is the causative agent44 J  VECT  BORNE  DIS  43, JUNE  2006
for most lethal forms of malaria, is known to lack a
functional Kreb’s cycle in its intra-erythrocytic stages
and hence solely rely on glycolysis for its energy
needs4. The glucose uptake is enhanced between 30
and 100 times greater than that of the uninfected
erythrocyte5 and almost all of it is converted to
lactate6. The increased metabolic activity of the
parasite during this period is reflected in the higher
activity levels of glycolytic enzymes compared to
those of the erythrocyte7. Since parasite has a single
gene for enolase and the activity of this enzyme is
essential for the operation of glycolysis8,
Plasmodium enolase protein can be a potential target
for antimalarial drugs. The infected RBC’s have ~15–
20 fold higher enolase activity as compared to
uninfected cells9 and as enolases are known to be
multifaceted proteins with several other non-
glycolytic functions10, it is likely that parasite enolase
may also be involved in novel biological function(s).
Further, apicomplexan enolases are phylogenetically
more closely related to plant enolases than to the
mammalian counterparts. Thus parasite enzyme may
constitute  a novel chemotherapeutic11 and/or dia-
gnostic12 target for malaria. With these consi-
derations, we have recently cloned, over expressed
and purified P. falciparum enolase13. Previously, we
have raised polyclonal antibodies against r-Pfen in
mice and rabbit. Here we report our recent attempts
to raise specific monoclonal antibodies against the
recombinant 6xHis-tagged enolase and a
pentadecapeptide encompassing the unique plant like
pentapeptide sequence.
Material & Methods
Preparation of r-Pfen: The 6xHis-tagged P.
falciparum enolase (r-Pfen) was expressed and puri-
fied as described earlier13.  Briefly, the protein was
expressed in E. coli strain XL1Blue. Cultures were
transformed with the recombinant plasmid and were
grown in Luria-Bertani medium containing 100 µg/
ml ampicillin at 37°C. Expression of enolase was
induced with IPTG (isopropyl-ß-D-thiogalacto-
pyranoside). The cells were lysed by incubation in
50 mM phosphate-Na+ (10 ml per g wet weight), pH
8 containing  300 mM NaCl, 1 mg/ml lysozyme, 1
mM PMSF for 30 min on ice and sonicated for six
cycles, 15 sec each, with 15 sec cooling between
successive bursts at 5 output in Branson Sonifier 450.
The lysate was centrifuged at 45,000 g for 30 min in
Beckman Ultracentrifuge (Model LE-80K, 70 Ti
Rotor). 6xHis-tagged recombinant-Pfen (r-Pfen) was
purified from soluble cell extract using Ni-NTA
sepharose (Quiagen) affinity chromatography.
Soluble cell extract was mixed with Ni-NTA slurry
(8 ml per litre culture) for one hour with gentle
agitation. Slurry was poured on a column and washed
with 50 bed volumes of 50 mM Na-phosphate, 40
mM imidazole, 300 mM NaCl, 1 mM PMSF, 5 mM
2-mercaptoethanol, pH 6 to remove nonspecifically
bound proteins. r-Pfen was eluted with 250 mM
imidazole in the same buffer. The enzyme was
extensively dialysed against phosphate buffer saline
(137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4,
1.8 mM KH2PO4, pH 7.4) (PBS). Purity was assessed
by SDS-PAGE and found to be >95% pure. Protein
concentration was determined using e280nm =
41400 M-1cm-1.
Cloning and expression of C-terminal & N-terminal
fragments of Pfen: C-terminal (aa 165–451, Mw~30
kDa) and N-terminal (aa 1–367, Mw ~40 kDa)
fragments of Pfen protein were generated in the
following manner. The Pfen has been cloned in Kpn
I and Pst I restriction sites of pQE30 vector. This
vector has a Bam H1 site before Kpn I site and there
is a Bam H1 site in the Pfen gene at position 50113.
The pQE30-Pfen plasmid was digested with Bam H1
and ethanol precipitated, linearised plasmid was self
ligated using T4 DNA ligase. This was used to
transform E. coli DH5-a and plated on to ampicillin
containing LB plates. This resulted in loss of 164
amino acids from N-terminal and a 6xHis tagged C-
terminal fragment of 282 amino acids could be
obtained (Pfen-N clone). Similarly, pQE30 has a
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Hind III site at position 1091 in Pfen. Thus digestion
of pQE30-Pfen with Hind III, resulted in a linear
fragment, which on self ligation produced a construct
having 6xHis tagged N-terminal sequence (1–367
aminoacids) of Pfen (Pfen-C clone).
Sequence alignment, 3D structure modeling and
peptide property calculation: The enolase peptide
sequences were aligned using CLUSTAL W for
homology comparisons14. The 3D structures of P.
falciparum enolase was modeled according to the
known X-ray structure of yeast enolase (PDB:
1EBG), using the SWISS-MODEL server15.
Hydrophilicity and net charge of the protein was
calculated using peptide property calculator (http://
www.innovagen.se/custom-peptide-synthesis/
peptide-property-calculator/peptide-property-
calculator.asp).
Coupling of peptide with bovine serum albumin (BSA):
The synthetic peptide -ELDGSKNEWGWSKSK-
was obtained from Mimotopes, Clayton South, VIC
Australia. The peptide was coupled to BSA using
the bifunctional reagent glutaraldehyde.  About 2 mg
of peptide and 6 mg of BSA were dissolved in 1 ml
of PBS. To this 1 ml of 0.4 % gluteraldehyde was
added in drop wise fashion along with stirring and
allowed to stand for 1 h at room temperature. Subse-
quently excess of gluteraldehyde was quenched by
the addition of 0.5 ml of 1 M glycine in PBS and
allowing it to incubate for 1 h. This was extensively
dialysed against PBS to remove all small molecules.
Immunisation of mice and establishment of
hybridoma: Monoclonal antibodies were generated
by the method of Kohler and Milstein16. About 50
µg r-Pfen or peptide coupled BSA (P-BSA) was
emulsified with Freund’s adjuvant and intra-peri-
toneally administered into six weeks old female
BALB/c mice. After four weekly injections, the mice
were immunised on a monthly basis for two months.
Five days before the fusion of splenocytes with
the mouse myeloma Sp2/0 cells, the mouse was
immunised once with 250 µg of the immunogen in
PBS. Antibody secreting clones were selected by
ELISA17. For ELISA, polystyrene Maxisorp plate
(Nunc, Roskilde, Denmark) was coated with antigen
by placing 100 µl of 0.5 mg/ml r-Pfen or P-BSA in
each well and allowing it to stand for 6 h at 37°C.
Unoccupied sites were blocked with 5% solution
of skimmed milk in PBS. Hybridoma culture
supernatants (or mAbs) were incubated with the
immobilised antigen at 4°C, overnight. Antibodies
bound to the antigens were detected by the addition
of rabbit anti-mouse IgG conjugated to horseradish
peroxidase (Boehringer Mannheim, Germany),
followed by addition of 0.5 mg/ml of the substrate
ABTS (2,2'-Azino-bis[3-ethylbenziazoline-6-
sulfonicacid]) (Boehringer Mannheim, Germany) (in
citrate phosphate buffer, pH 4.3) containing 0.03%
H2O2 and measuring absorbance values at 405 nm
in the ELISA reader (EL808 Ultra Microplate reader,
Biotek Instruments Inc). ELISA experiments with
yeast and rabbit muscle enolases were performed,
following the same protocol as described earlier13.
Finally two mAbs were generated against r-Pfen and
six against P-BSA.
Electrophoresis and Western blotting: Proteins were
resolved on an SDS/12% polyacrylamide gel18 and
visualised by staining with coomassie brilliant blue
R-250. For Western blotting, crude cellular extracts
and/or purified r-Pfen were separated on a SDS-gel
and were transferred to nitrocellulose membrane
using semi-dry Western transfer apparatus (Bio-Rad
Laboratories, Inc., Hercules, CA, USA) at a constant
voltage (20 V) for 35 min. The membranes were
blocked with 5% skimmed milk in PBS (NaCl/Pi;
137 mM NaCl, 2.7 mM KCl, 10.0 mM Na2HPO4,
1.8 mM KH2PO4, pH 7.4) containing 0.05% Tween-
20 for 1 h. The blots were treated with the mouse
polyclonal or monoclonal antibodies and secondary
anti-mouse IgG coupled to horseradish peroxidase.
Both antibodies were used at 1: 1000 dilution. The
immuno-blots were developed using dianilino-
benzene substrate.46 J  VECT  BORNE  DIS  43, JUNE  2006
For the preparation of P. falciparum (strain 3D7)
extracts, intracellular parasites from asexual stages
were released from infected RBCs by saponin lysis
and collected by centrifugation. Parasite pellet was
washed with PBS and dissolved in SDS-PAGE
sample buffer. The total crude parasite extract was
used for Western blot analysis. Typically each lane
had extract from ~105 parasites. Protein extracts from
human lymphocytes were prepared by collecting
blood in anticoagulant EDTA and separating the
lymphocytes at 450xg for 15 min at 4°C, on a Ficoll
Histopaque density gradient (Amersham Pharmacia
Biotech Inc., Piscatway, NJ, USA). The buffy coat
was used as the source of human lymphocytes. Crude
protein extract was obtained by sonicating the
lymphocytes in PBS containing 1 mg/ml each of
pepstatin and leupeptin.
Indirect immunofluorescence assay: An immuno-
fluorescence assay was performed on the blood
smears  obtained from P. falciparum human
erythrocyte culture. The smears were fixed for 30
sec using chilled methanol and treated with mono-
clonal antibody  at a dilution of 1 : 2 at room tempe-
rature for 1 h. This was then stained for 45 min with
Alexa Fluor 488-conjugated anti-rabbit IgG. Parasite
nuclei were stained with DAPI at a final conce-
ntration of 1 µg/ml. The necessary washes were given
after each antibody incubation step, and slides were
mounted under glass cover slips in 5 µl vectashield
mounting medium. Slides were examined using a
Nikon fluorescence microscope19.
Results & Discussion
Monoclonal antibodies against r-Pfen: Although
enolases are highly conserved across the species,
interesting differences have been noted between
apicomplexan parasite enolases and mammalian
homologues20. One of the main differences is the
presence of a pentapeptide sequence104 EWGWS108
in P. falciparum enolase. A CLUSTAL-W sequence
alignment14 for enolases from several species around
this insert is shown in Fig. 1(A). If we model the 3D
structure of P. falciparum enolase using X-ray
structure of yeast enolase (PDB:1EBG) (Fig. 1 B),
this pentapeptide insert forms a part of a surface loop
structure.  It is likely that if this region of parasite
Fig. 1: (A) Partial aminoacid sequence alignment of enolases
from several different species. A characteristic plant
like pentapeptide insert is present in apicomplexan
parasites; & (B) Model structure of P. falciparum
enolase showing the localisation of this insert and
flanking region (97ELDGSKNEWGWSKSK111) in a
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enolase is antigenic, we may be able to obtain specific
antibodies against this region. For the generation of
monoclonal antibodies, mice were challenged with
r-Pfen and splenocytes were fused with mouse
myeloma cell lines to obtain antibody secreting
hybridomas. Initially 10 clones were obtained.
However, after few rounds of cell cycle, only two of
the clones (D11 and D12) remained as secretors.
These parent clones secreted IgG class of antibodies
and were sub-cloned to obtain two monoclonals
(1D12B6 and 1D11A6). These clones had an
antibody titre of 1 : 1000. We also collected the anti-
sera from these mice and compared the specificity
of polyclonal and monoclonal antibodies against full
length r-Pfen. Results are presented in Fig. 2(A).
Equal amounts (10 µg) of r-Pfen, yeast and rabbit
muscle enolases were run on a 12% SDS-PAGE and
blotted on nitrocellulose membranes. These were
then probed with either polyclonal sera or with
Fig. 2: (A) Comparison of anti-enolase antibodies cross reactivity with (a) r-Pfen, (b) yeast enolase, and (c) rabbit
muscle enolase. 10 µg of each enolase protein was run on a SDS-PAGE. First panel shows commassie staining,
second panel is a Western blot probed with mouse polyclonal antibody (1:5000) and third panel is probed with
monoclonal antibody supernatant 1D12B6 (1 : 10); (B) Mapping of antigenic site(s) of r-Pfen for monoclonal
antibodies. Full length r-Pfen (10 µg, MW 51 kDa in lane a) and a mixture of Pfen-N (MW 40 kDa) and Pfen-
C (MW 30 kDa) (8 µg each in lane b) were separated on a SDS-PAGE gel. First panel is stained with commassie
blue. Second and third panels are Western blots probed with 1D12B6 and 1D11A6 monoclonal antibodies.
Note the absence of reactivity with Pfen-C fragment in second and third panel indicating that both these
monoclonals are specific for N-terminal sequence of Pfen
monoclonal (1D12B6) antibodies. Polyclonal
antibodies exhibit lot more reactivity with r-Pfen as
compared to yeast and rabbit proteins at a dilution
of 1 : 5000. Although these proteins are highly
homologous (61–68%), we observed considerably
high specificity against r-Pfen. However, these
polyclonal antibodies were not completely exclusive
for r-Pfen, and cross reacted with the yeast and rabbit
enolases (Fig. 2). In comparison monoclonal
antibody 1D12B6 (1:10), exclusive reactivity to r-
Pfen was observed (Fig. 2).
In order to map the antigenic region(s) for the
monoclonal antibodies, we generated two deletion
clones of r-Pfen covering N-terminal (Pfen-N, aa 1–
367) and C-terminal (Pfen-C, aa 165–451) as 6xHis
tagged proteins, expressed in Escherichia coli and
purified by Ni-NTA chromatography. These deletion
proteins were used to map the location of specific48 J  VECT  BORNE  DIS  43, JUNE  2006
antigenic epitopes against which the monoclonals are
directed.  r-Pfen and a mixture of Pfen-C and Pfen-
N (8 µg each) were separated on a 12% SDS-PAGE
and probed with two monoclonal antibodies. Results
are presented in Fig. 2(B). Commassie stained panel
shows the presence of full length and deletion
fragments of Pfen at appropriate sizes. In the Western
blot, we observed that both monoclonal antibodies
bind to epitopes located on the Pfen-N fragment.
Absence of cross reactivity with Pfen-C would
suggest that the antigenic site is located in the first
165 amino acids of r-Pfen. It is interesting to note
Fig. 3: (A) SDS-PAGE analysis of peptide coupled BSA (P-BSA) (lane 1). Lane 2 is pure BSA. Chemical cross
linking of peptide also cross links BSA dimers (lane 1, two smears); (B) Reactivity of parent peptide
clone supernatants (1C1, 1C9, 1D12 and 1E6) against P-BSA and BSA as measured by ELISA. Plates
were coated with 500 ng of P-BSA or BSA and probed with different supernatant antibodies; and (C)
Competitive displacement of antibodies by the synthetic peptide. Supernatant antibodies were incubated
with 5 or 15 µg of peptide for 30 min and then used to probe the ELISA plates coated with 500 ng of
P-BSA
that the unique plant like pentapeptide insert
(-104EWGWS108-) is a part of this sequence.
Antibodies against peptide (ELDGSKNEWGWS-
KSK) coupled bovine serum albumin: In order to
generate a specific antibody directed against the
unique pentapeptide sequence in Pfen, we exam-
ined the properties of the flanking sequences on
either side of this insert. We selected the region
which includes maximal number of lysines in
the sequence to make it hydrophilic, soluble and
antigenic. A sequence of fifteen amino acids,PAL-BHOWMICK et al : MONOCLONAL ANTIBODIES AGAINST P.  FALCIPARUM ENOLASE 49
97ELDGSKNEWGWSKSK111 was chosen. This
sequence had an average hydrophilicity value of 0.7
on Hopp & Woods scale21 and is likely to be
antigenic. In general, it is believed that if a molecule
is highly charged, it may be difficult to create the
complementary antibody combining site with charge
groups. The selected peptide has a good balance of
electronegative and electropositive residues so as to
bear zero net charge at pH ~7. Thus at physiological
pH, it is not likely to have any net charge. As small
molecules are known to be feeble immunogens and
evoke very weak immune response, we coupled this
peptide to bovine serum albumin  using gluter-
aldehyde. On SDS-PAGE this coupled conjugate
gave two smears which are likely to be due to
coupling of the peptide with monomeric and dimeric
forms of the BSA (P-BSA) (Fig. 3A). Peptide
conjugated-BSA was used to immunise the mice and
splenocytes from these mice were used to generate
hybridomas. This resulted in the isolation of four
secreting parent clones.  The antibodies secreted by
all these clones were of IgM type. Specificity of
these monoclonal antibodies for BSA and P-BSA
was examined by ELISA. Results are presented in
Fig. 3 (B).  These monoclonals had very poor cross
reactivity to BSA as compared to P-BSA. To further
confirm that antibodies are peptide specific, we
performed a peptide competitive displacement
experiment. ELISA was performed in the presence
of 5 and 15 mg of peptide. The ELISA values
decreased with respect to the control for all four
clones (Fig. 3C), suggesting that indeed these
antibodies are directed against the peptide.
It is a common observation that antibodies raised
against peptides are usually not the native protein
reactive antibodies (NPRA). Such situations arise
when either the antigenic epitope is buried or inacce-
ssible in native protein or the segment containing
the peptide sequence in native protein is too rigid to
allow the anti-peptide antibody to ‘mold’ it to fit the
binding site. We examined the question whether the
anti-peptide antibodies bind to the native protein by
measuring the cross reactivity of the antibodies
against r-Pfen (native full length enolase) using
ELISA. Fig. 4(A) shows the reactivity of two of the
parent clones (1D12 and 1C9) against r-Pfen and P-
BSA.  Both antibodies were able to interact with the
Fig. 4: (A) Reactivity of anti-peptide antibody parent clone supernatants against native enolase as measured by ELISA.
Plates were coated with 500 ng of enolase (r-Pfen) or P-BSA; & (B) Western blot analysis for reactivity of native
enolase with monoclonal antibody 1C9G12. 10 mg of r-Pfen was resolved on 8% native PAGE and (a) visualised
by commassie staining, (b) blot probed with anti-r-Pfen polyclonal antibody (1 : 5000), and (c) blot probed with
1C9G12 monoclonal antibody (1 : 20)50 J  VECT  BORNE  DIS  43, JUNE  2006
Fig. 5: Specificity of different monoclonal antibodies raised against P-BSA: (A) comparison of ELISA reactivity of monoclonal
antibodies against 500 ng of different antigens (a), (b) and (c) are NT, C1 and C0 regions of ribosomal PfP0 protein of
P. falciparum22, (d) BSA, (e) human lymphocyte extract, (f) rabbit muscle enolase, (g) yeast enolase, and (h) P-BSA;
and  (B) Comparison of immuno-blot reactivity against (a) rabbit muscle enolase, (b) yeast enolase, (c) r-Pfen; and (d)
P. falciparum extract, run on 12% SDS-PAGE gel and probed with 1C9G12 monoclonal antibody (1 : 20)
Fig. 6: Immunofluorescence assay with P. falciparum
infected human red blood cells treated with
(A) DAPI (1 µg ml-1); (B) 1C9G12 (1 : 2)
monoclonal antibody;  and (C) bright field
picture. Two different fields are shown. Three
horizontal panels represent the same field.
Uninfected erythrocytes are marked by arrows
 (A) (B)
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native enolase.
mAb 1C9G12 was tested on a blot of a native gel to
check whether it could interact with various
oligomeric forms of the enolase.  In Fig. 4(B), panel
(a) shows a commassie stain of r-Pfen in a native
gel. Two major bands are observed and both of these
bands cross react with polyclonal (panel b) as well
as monoclonal antibody (panel c). Cross reactivity
with the native enolase protein supports the con-
clusion that the antigenic peptide sequence is located
on the surface in the 3D native structure of Pfen.
The modeled structure of Pfen also predicts that this
pentapeptide containing sequence forms a surface
loop in the folded protein (Fig. 1B).
Six different anti-peptide monoclonal antibodies
were then obtained from three different parent
clones—1D2A6, 1D12F4, 1D12D9, 1C9G12,
1C1A5 and 1C1C12. Of these, the six anti P-BSA
mAbs were assayed for specificity against several
different antigens. Antigens used were N-terminal
and C-terminal fragments of P. falciparum ribosomal
protein P0 (PfP0-NT, C1 region of PfP0), C-terminal
fragment of human P0, bovine serum albumin,
human lymphocyte extract, enolases from rabbit and
yeast and P-BSA. Results are presented in Fig. 5(A).
The high reactivity of all monoclonals with P-BSA
and negligible cross reactivity with other antigens,
reiterates our earlier conclusion that these
monoclonals are highly specific for r-Pfen derived
peptide. High selectivity in cross reactivity of mono-
clonal 1C9G12 is further evident from the
immunoblot of a 12% SDS-PAGE gel, where rabbit
muscle and yeast enolases fail to cross react, whereas
r-Pfen and enolase from parasite extract gets
unequivocally identified (Fig. 5B).
We also examined the ability of 1C9G12 mono-
clonal antibody to interact with P. falciparum in
erythrocyte cultures. In an immuno-fluorescence
assay (IFA), the parasite infected RBC’s could be
visualised by staining with DAPI and same cells
could also be stained with anti-peptide antibody
1C9G12 (Fig. 6). As the parasite culture used here
is not synchronised, several different stages of
parasite are visible and all of these stages are stained
with the antibody. This confirms our finding from
homology modeling that this epitope is exposed on
the surface of the molecule. It is important to note
that all the anti-peptide monoclonal antibodies
obtained are of IgM class.
Conclusion
We have raised monoclonal antibodies against P.
falciparum enolase using two different antigens, (i)
with native recombinant enolase protein (r-Pfen), and
(ii) with a unique pentapeptide sequence containing
peptide coupled to BSA (P-BSA). Two monoclonals
(1D12B6 and 1D11A6) obtained with r-Pfen as
antigen, are of IgG class and could be mapped to
bind to antigenic site(s) located in the N-terminal
region (aa 1–165) of the Pfen. Six monoclonals
obtained against the P-BSA were of IgM type and
are able to bind to the native enolase as confirmed
by ELISA, Western blotting and immuno-
fluorescence assay on parasite culture. All these
monoclonals are very specific for P. falciparum
enolase and do not cross react to rabbit muscle or
yeast enolases. Since this peptide encompasses the
unique pentapeptide insert which is a characteristic
feature of enolases from apicomplexan parasites, the
observed cross reactivity with native Pfen can be
taken as evidence for the surface localisation of this
peptide sequence in Pfen native structure. The high
specificity of these monoclonals against Pfen makes
them excellent reagents for parasite detection in
infected blood samples.
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